AbbVie announced a definitive agreement to acquire Pharmacyclics and its flagship asset Imbruvica for $21 billion. Under the terms of the transaction, announced March 4, AbbVie will pay$261.25 per share, comprised of a mix of cash and AbbVie equity.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
